Singapore Market Roundup, Singapore Market Roundup

Singapore Market Roundup

Thematic (Sector/Industry)

<ul><li>Q&amp;M aims to improve margins after expansion phase, says Phillip Securities, indicating positive outlook for the company. </li><li>DBS remains optimistic on GuocoLand following strong 1HFY2025 performance, highlighting potential growth opportunities. </li><li>Wilmar faces challenges in China operations, but UOB Kay Hian anticipates a brighter future ahead, suggesting positive changes. Analysts raise DBS target prices above $51, predicting capital returns for investors.</li></ul>

Q&amp;M aims to improve margins after expansion phase, says Phillip Securities, indicating positive outlook for the company. DBS remains optimistic on GuocoLand following strong 1HFY2025 performance, highlighting potential growth opportunities. Wilmar faces challenges in China operations, but UOB Kay Hian anticipates a brighter future ahead, suggesting positive changes. Analysts raise DBS target prices above $51, predicting capital returns for investors.

Singapore Market Roundup (12-Feb-2025): Q&M aims to improve margins post expansion: Phillip Securities.

<ul><li>Phillip Securities believes Q&amp;M will reverse margin trends as expansion phase ends; DBS bullish on GuocoLand after strong 1HFY2025 results.</li><li>UOB Kay Hian optimistic about Wilmar's improving China operations; analysts raise DBS's target prices above $51 on strong capital returns.</li><li>Analysts positive on CLAR post FY2024 results; OCBC Investment Research raises DBS's target price to $50 after record profits in FY2024 under Piyush Gupta's leadership.</li></ul>

Phillip Securities believes Q&amp;M will reverse margin trends as expansion phase ends; DBS bullish on GuocoLand after strong 1HFY2025 results.UOB Kay Hian optimistic about Wilmar's improving China operations; analysts raise DBS's target prices above $51 on strong capital returns.Analysts positive on CLAR post FY2024 results; OCBC Investment Research raises DBS's target price to $50 after record profits in FY2024 under Piyush Gupta's leadership.

Singapore Market Roundup (11-Feb-2025): Q&M reversing margin trends as expansion phase ends - Phillip Securities.

<ul><li>DBS may need to accelerate expansion into Malaysian market due to urgency of JS-SEZ project, according to CreditSights.</li><li>Singtel is focused on enhancing shareholder value, as confirmed by UOBKH, which also maintains a buy rating for KORE and Prime post office return mandate.</li><li>Venture Corp receives a 'buy' rating from UOB Kay Hian due to promising medium-term growth prospects, while Maybank predicts S-REIT distributions to stabilize by 2H2025 and growth in FY2026.</li></ul>

DBS may need to accelerate expansion into Malaysian market due to urgency of JS-SEZ project, according to CreditSights.Singtel is focused on enhancing shareholder value, as confirmed by UOBKH, which also maintains a buy rating for KORE and Prime post office return mandate.Venture Corp receives a 'buy' rating from UOB Kay Hian due to promising medium-term growth prospects, while Maybank predicts S-REIT distributions to stabilize by 2H2025 and growth in FY2026.

Singapore Market Roundup (21-Jan-2025): DBS must accelerate Malaysia expansion due to JS-SEZ urgency - CreditSights

<ul><li>Maybank forecasts stable S-REIT distributions in the second half of 2025 with growth expected in fiscal year 2026.</li><li>CGSI remains optimistic on Singtel and KDC despite US artificial intelligence restrictions.</li><li>UOBKH anticipates higher dividends from DBS and OCBC in the future. Maybank takes a 'neutral' stance on the Singapore healthcare sector.</li></ul>

Maybank forecasts stable S-REIT distributions in the second half of 2025 with growth expected in fiscal year 2026.CGSI remains optimistic on Singtel and KDC despite US artificial intelligence restrictions.UOBKH anticipates higher dividends from DBS and OCBC in the future. Maybank takes a 'neutral' stance on the Singapore healthcare sector.

Singapore Market Roundup (20-Jan-2025): Maybank: S-REIT distributions stable by 2H2025, grow FY2026+

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

Equity Bottom-Up

<ul><li>The global Healthcare sector has expanded at a rapid pace over the recent years, driven by significant medical advances, accelerated drug approval processes for high unmet needs and overall increased access to healthcare.</li><li>The iEdge SG All Healthcare Index, which tracks the performance of the listed healthcare segment in Singapore, generated a 5% decline (in total return terms) in the first 2 months of 2023, with the top 10 constituents by weightage, averaging 0.8% gain in total returns.</li><li>Q & M Dental Group, reported a 12% decline in full year total FY22 revenue as Covid-19 testing revenue significantly decreased.</li></ul>

The global Healthcare sector has expanded at a rapid pace over the recent years, driven by significant medical advances, accelerated drug approval processes for high unmet needs and overall increased access to healthcare.The iEdge SG All Healthcare Index, which tracks the performance of the listed healthcare segment in Singapore, generated a 5% decline (in total return terms) in the first 2 months of 2023, with the top 10 constituents by weightage, averaging 0.8% gain in total returns.Q & M Dental Group, reported a 12% decline in full year total FY22 revenue as Covid-19 testing revenue significantly decreased.

Bright Spots in Singapore's Healthcare sector

Singapore

Q & M Dental Group (Singapore) Limited operates dental clinics. The Company offers aesthetic, children's and general dentistry; fits crowns, dentures and braces; and offers bleeding gum treatment, gum surgery and oral surgery; and treats snoring and teeth grinding.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Q & M Dental Group (Singapore) (QNM SP)

Singapore Market Roundup (12-Feb-2025): Q&M aims to improve margins post expansion: Phillip Securities.

Analysts are optimistic about Q&M, GuocoLand, Wilmar, and DBS with positive outlooks on margin trends, performance, future growth, and target prices.

Singapore Market Roundup

Singapore Market Roundup (11-Feb-2025): Q&M reversing margin trends as expansion phase ends - Phillip Securities.

Analysts are optimistic about multiple Singaporean companies such as Q&M, GuocoLand, Wilmar, and DBS, with target prices rising and strong...

Singapore Market Roundup

Singapore Market Roundup (21-Jan-2025): DBS must accelerate Malaysia expansion due to JS-SEZ urgency - CreditSights

DBS urged to accelerate expansion into Malaysia as Singtel aims to enhance shareholder value, UOBKH maintains buy ratings for KORE and Prime,...

Singapore Market Roundup

Singapore Market Roundup (20-Jan-2025): Maybank: S-REIT distributions stable by 2H2025, grow FY2026+

Maybank and UOBKH offer insights on S-REITs, Singtel, KDC, DBS, OCBC, and Singapore healthcare sector predicting stable distributions, bullish...

Singapore Market Roundup

Bright Spots in Singapore's Healthcare sector

The global Healthcare sector has expanded at a rapid pace over the recent years, driven by significant medical advances, accelerated drug approval...

Singapore Exchange Ltd (SGX)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)